Shankus Acme Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 08-12-2024
- Paid Up Capital ₹ 0.10 M
as on 08-12-2024
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.41 M
as on 08-12-2024
- Revenue 62.28%
(FY 2022)
- Profit 879.81%
(FY 2022)
- Ebitda 582.31%
(FY 2022)
- Net Worth 54.08%
(FY 2022)
- Total Assets -8.13%
(FY 2022)
About Shankus Acme Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.41 M.
Dashrathbhai Patel, Dilip Chaudhary, and Javal Patel serve as directors at the Company.
- CIN/LLPIN
U24230GJ2012PTC069152
- Company No.
069152
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Feb 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Mahesana, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Shankus Acme Pharma Private Limited offer?
Shankus Acme Pharma Private Limited offers a wide range of products and services, including Hair Care, Hair Growth for Men.
Who are the key members and board of directors at Shankus Acme Pharma?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Javal Patel  | Director | 29-Nov-2016 | Current |
| Dashrathbhai Patel | Director | 24-Feb-2012 | Current |
| Dilip Chaudhary | Director | 24-Feb-2012 | Current |
Financial Performance and Corporate Structure Insights of Shankus Acme Pharma.
Shankus Acme Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 62.28% increase. The company also saw a substantial improvement in profitability, with a 879.81% increase in profit. The company's net worth Soared by an impressive increase of 54.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shankus Acme Pharma?
In 2021, Shankus Acme Pharma had a promoter holding of 65.00% and a public holding of 35.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Acmedix Pharma LlpActive 6 years 7 months
Dashrathbhai Patel, Dilip Chaudhary and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 15 Feb 2023 | ₹2.41 M | Open |
How Many Employees Work at Shankus Acme Pharma?
Shankus Acme Pharma has a workforce of 45 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shankus Acme Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shankus Acme Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
